Public Assessment Report

Decentralised Procedure

Ibandronic Acid 6 mg Concentrate for solution for infusion

(ibandronic acid)

UK/H/4472/001/DC

UK licence number: PL 24598/0036

Noridem Enterprises Limited
LAY SUMMARY

On 16 April 2013, the Medicines and Healthcare products Regulatory Agency (MHRA) granted a Marketing Authorisation (licence) to Noridem Enterprises Limited for the medicinal product, Ibandronic Acid 6 mg Concentrate for Solution for Infusion (PL 24598/0036; UK/H/4472/001/DC). This is a prescription-only medicine (POM).

Ibandronic Acid 6 mg Concentrate for Solution for Infusion is indicated in adults to help prevent:
- bones from breaking (fractures);
- other bone problems that may need surgery or radiotherapy.

Ibandronic Acid 6 mg Concentrate for Solution for Infusion is indicated in adults who have breast cancer which has spread to bones (called bone “metastases”). It can also be prescribed for a raised calcium level in the blood due to a tumour.

Ibandronic Acid 6 mg Concentrate for Solution for Infusion contains the active ingredient ibandronic acid, which belongs to a group of substances called bisphosphonates. Ibandronic acid works by reducing the amount of calcium that is lost from the bones. This helps to stop the bones from getting weaker.

No new or unexpected safety concerns arose from this application and it was therefore judged that the benefits of Ibandronic Acid 6 mg Concentrate for Solution for Infusion outweigh the risks and a Marketing Authorisation was granted.
# TABLE OF CONTENTS

Module 1: Information about initial procedure          Page 4
Module 2: Summary of Product Characteristics         Page 5
Module 3: Patient Information Leaflet                Page 6
Module 4: Labelling                                  Page 7
Module 5: Scientific discussion during initial procedure
   I Introduction                                      Page 10
   II About the product                               Page 12
   III Scientific Overview and discussion             Page 13
      III.1 Quality aspects                           Page 13
      III.2 Non-clinical aspects                      Page 16
      III.3 Clinical aspects                         Page 17
   IV Overall conclusions and benefit-risk assessment Page 18
Module 6     Steps taken after initial procedure       Page 19
# Module 1

## Information about Initial Procedure

<table>
<thead>
<tr>
<th><strong>Product Name</strong></th>
<th>Ibandronic Acid 6 mg Concentrate for Solution for Infusion</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type of Application</strong></td>
<td>Generic, Article 10.1</td>
</tr>
<tr>
<td><strong>Active Substance</strong></td>
<td>Ibandronic acid</td>
</tr>
<tr>
<td><strong>Form</strong></td>
<td>Concentrate for solution for infusion</td>
</tr>
<tr>
<td><strong>Strength</strong></td>
<td>6mg/6ml</td>
</tr>
</tbody>
</table>
| **MA Holder** | Noridem Enterprises Limited  
Evagorou & Makariou,  
Mitsi Building 3,  
Office 115,  
1065 Nicosia,  
Cyprus |
| **Reference Member State (RMS)** | UK |
| **Concerned Member States (CMS)** | Austria, Germany, Greece, Ireland, Spain and Poland |
| **Procedure Number** | UK/H/4472/001/DC |
| **Timetable** | Day 210 – 14 March 2013 |
Module 2

Summary of Product Characteristics

In accordance with Directive 2010/84/EU, the Summaries of Product Characteristics (SmPCs) for products granted Marketing Authorisations at a national level are available on the MHRA website.
Module 3

Patient Information Leaflet

In accordance with Directive 2010/84/EU, the Patient Information Leaflets (PILs) for products granted Marketing Authorisations at a national level are available on the MHRA website.
Module 4

Labelling
Module 5

Scientific discussion during initial procedure

I Introduced

Based on the review of the data on quality, safety and efficacy, the member states considered that the application for Ibandronic Acid 6 mg Concentrate for Solution for Infusion (PL 24598/0036; UK/H/4472/001/DC) could be approved. The product is a prescription-only medicine (POM) indicated in adults for:

- prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases
- treatment of tumour-induced hypercalcaemia with or without metastases.

The application was submitted using the Decentralised Procedure (DCP), with the UK as Reference Member State (RMS) and Austria, Germany, Greece, Ireland, Spain and Poland as Concerned Member States (CMSs). The application was submitted under Article 10(1) of Directive 2001/83/EC, as amended, claiming to be a generic medicinal product of Bondronat 6 mg/6 ml concentrate for infusion, which was registered via the Centralised Procedure (EU/1/96/012/011-013) on 25 June 1996 in the UK. The Marketing Authorisation Holder was originally Boehringer Mannheim GmbH and subsequently changed to Roche Registration Limited.

Ibandronic acid is a synthetic bisphosphonate analogue of pyrophosphate, and an inhibitor of osteoclast-mediated bone resorption. Ibandronic acid is used to prevent skeletal related events in patients with breast cancer and bone metastasis, and to treat tumour-induced hypercalcaemia and osteoporosis.

No new non-clinical studies were performed, which is acceptable given that the application was based on being a generic medicinal product of an originator product that has been in clinical use for over 10 years.

No new clinical data have been submitted and none are required for this type of application. A bioequivalence study was not necessary to support this application for a parenteral product (aqueous solution).

The RMS has been assured that acceptable standards of Good Manufacturing Practice (GMP) are in place for this product type at all sites responsible for the manufacture and assembly of this product. Evidence of compliance with GMP has been provided for the named manufacturing and assembly sites. For manufacturing sites within the Community, the RMS has accepted copies of current manufacturer authorisations issued by inspection services of the competent authorities as certification that acceptable standards of GMP are in place at those sites.

For manufacturing sites outside the community, the RMS has accepted copies of current GMP Certificates or satisfactory inspection summary reports, ‘close-out letters’ or ‘exchange of information’ issued by the inspection services of the competent authorities (or those countries with which the EEA has a Mutual Recognition Agreement for their own territories) as certification that acceptable standards of GMP are in place at those non-Community sites.
The RMS and CMS considered that the application could be approved at the end of procedure (Day 210) on 14 March 2013. After a subsequent national phase, a licence was granted in the UK on 16 April 2013.
II. ABOUT THE PRODUCT

<table>
<thead>
<tr>
<th>Name of the product in the Reference Member State</th>
<th>Ibandronic Acid 6 mg Concentrate for Solution for Infusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name(s) of the active substance(s) (INN)</td>
<td>Ibandronic acid as ibandronate sodium monohydrate</td>
</tr>
<tr>
<td>Pharmacotherapeutic classification (ATC code)</td>
<td>Bisphosphonates (M05B A06)</td>
</tr>
<tr>
<td>Pharmaceutical form and strength(s)</td>
<td>Concentrate for solution for infusion 6 mg/6 ml</td>
</tr>
<tr>
<td>Reference numbers for the Decentralised Procedure</td>
<td>UK/H/4472/001/DC</td>
</tr>
<tr>
<td>Reference Member State</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Member States concerned</td>
<td>Austria, Germany, Greece, Ireland, Spain and Poland</td>
</tr>
<tr>
<td>Marketing Authorisation Number(s)</td>
<td>PL 24598/0036</td>
</tr>
<tr>
<td>Name and address of the authorisation holder</td>
<td>Noridem Enterprises Ltd Evagorou &amp; Makariou, Miti Building 3, Office 115, 1065 Nicosia, Cyprus</td>
</tr>
</tbody>
</table>
III SCIENTIFIC OVERVIEW AND DISCUSSION

III.1 QUALITY ASPECTS

ACTIVE SUBSTANCE

Ibandronic acid

Nomenclature:

INN: Ibandronate sodium monohydrate

Chemical name: 3-(N-methyl-N-pentyl) amino-1-hydroxypropane-1,1-diphosphonic acid, monosodium salt, monohydrate

Structure:

![Ibandronic Acid Structure](image)

Molecular formula: C_{9}H_{22}O_{7}NP_{2}Na-H_{2}O

Molecular weight: 359.24 g/mol

Physical form: A white to off-white powder

Solubility: Freely soluble in water and practically insoluble in organic solvents such as methanol, ethanol and dimethyl formamide.

The active substance, ibandronic acid, is not the subject of a European Pharmacopeia (Ph. Eur.) or British Pharmacopeia (B.P.) monograph.

Synthesis of the active substance from the designated starting materials has been adequately described and appropriate in-process controls and intermediate specifications are applied. Satisfactory specification tests are in place for all starting materials and reagents and these are supported by relevant Certificates of Analysis. Appropriate proof-of-structure data have been supplied. All potential known impurities have been identified and characterised.

An appropriate specification is provided for the active substance. Analytical methods have been appropriately validated and are satisfactory for ensuring compliance with the relevant specifications. Batch analysis data are provided and comply with the proposed specification.

Satisfactory Certificates of Analysis have been provided for all working standards.

Suitable specifications have been provided for all packaging used. The primary packaging has been shown to comply with current guidelines concerning contact with foodstuff.

Appropriate stability data have been generated to support a suitable retest period when stored in the proposed packaging.
MEDICINAL PRODUCT

Other Ingredients
Other ingredients consist of the pharmaceutical excipients, sodium chloride, acetic acid (E260), sodium acetate (E262) and water for injections. Appropriate justification for the inclusion of each excipient has been provided.

All excipients comply with their respective European Pharmacopoeia monographs. Certificates of Analysis have been provided for all excipients, showing compliance with the proposed specifications.

The applicant has provided a declaration confirming that there are no materials of human or animal origin contained in or used in the manufacturing process for the proposed product. None of the excipients are sourced from genetically modified organisms (GMO).

Pharmaceutical development
The objective of the development programme was to produce a product that could be considered a generic medicinal product of Bondronat 6 mg/6 ml concentrate for infusion (Roche Registration Limited).

Suitable pharmaceutical development data have been provided for this application.

Comparative physicochemical data have been provided for this product and the reference product Bondronat 6 mg/6 ml concentrate for infusion (Roche Registration Limited).

Manufacture
A satisfactory batch formula has been provided for the manufacture of the product, along with an appropriate account of the manufacturing process. The manufacturing process has been validated with pilot-scale batches and has shown satisfactory results. The Marketing Authorisation Holder has committed to performing process validation studies on future full-scale production batches.

Finished product specification
The finished product specification is acceptable. Test methods have been described and have been validated adequately. Batch data have been provided and comply with the release specifications. Certificates of Analysis have been provided for all working standards used.

Container Closure System
The finished product is supplied in packs containing 1, 5 and 10 vials (6 ml type 1 glass vials). The vials are closed with rubber stoppers complying with Ph.Eur.

Not all pack sizes may be marketed.

Satisfactory specifications and certificates of analysis for the primary packaging material have been provided. All primary packaging is controlled to European Pharmacopoeia standards and complies with guidance concerning materials in contact with parenteral products.
Stability of the Product
Finished product stability studies have been conducted in accordance with current guidelines on batches of finished product in the packaging proposed for marketing. Based on the results, a shelf-life of 2 years has been proposed, with no special storage instructions for the product when stored in the vial.

Chemical and physical in-use stability has been shown for 24 hours under refrigeration and 25 °C when the product is diluted with either 0.9 % sodium chloride or 5 % glucose to a concentration of 0.012 mg/ml.

It is stated that, after dilution, from a microbiological point of view, the solution for infusion should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2–8 °C.

Suitable post approval stability commitments have been provided to continue stability testing on batches of the finished product.

Bioequivalence Study
A bioequivalence study was not necessary to support this application for an aqueous solution that is a parenteral product.

Summary of Product Characteristics (SmPC), Patient Information Leaflet (PIL) and Labels
The SmPC, PIL and labels are satisfactory from a pharmaceutical perspective.

A package leaflet has been submitted to the MHRA along with results of consultations with target patient groups (‘user testing’), in accordance with Article 59 of Council Directive 2001/83/EC, as amended. The results indicate that the package leaflet is well-structured and organised, easy to understand and written in a comprehensive manner. The test shows that the patients/users are able to act upon the information that the leaflet contains.

Marketing Authorisation Application (MAA) Form
The MAA form is satisfactory from a pharmaceutical perspective.

Expert Report (Quality Overall Summary)
A satisfactory quality overall summary is provided, and has been prepared by an appropriately qualified expert. The CV of the expert has been supplied.

Conclusion
All pharmaceutical issues have been resolved and the quality grounds for this application are considered adequate. There are no objections to approval of Ibandronic Acid 6 mg Concentrate for Solution for Infusion from a pharmaceutical point of view.
III.2 NON-CLINICAL ASPECTS

As the pharmacodynamic, pharmacokinetic and toxicological properties of ibandronic acid are well-known, no new non-clinical data have been submitted and none are required.

The applicant’s non-clinical expert report has been written by an appropriately qualified person and is satisfactory; providing an appropriate review of the pharmacology and toxicology of ibandronic acid.

Suitable justification has been provided for the non-submission of an environmental risk assessment. As the application is for a generic version of an already authorised product, it is not expected that environmental exposure will increase following approval of the Marketing Authorisation for the proposed product.

The grant of a Marketing Authorisation is recommended.
III.3 CLINICAL ASPECTS

Clinical Pharmacology
No new clinical pharmacology data have been submitted and none are required for applications of this type. A bioequivalence study was not necessary to support this application for an aqueous parenteral product. According to CHMP guidance, bioequivalence studies are not generally required for parenteral aqueous solutions (CPMP/EWP/QWP/1401/98 Rev.1/Corr (Note for guidance on the Investigation of Bioequivalence).

Efficacy
No new efficacy data have been submitted and none are required for this type of application.

Safety
No new safety data have been submitted with this application and none are required. No new or unexpected safety concerns arose from this application. As an active ingredient, Ibandronic acid has a well-established safety profile and an acceptable level of safety in the proposed indications.

Summary of Product Characteristics (SmPC), Patient Information Leaflet (PIL) and Labels
The SmPC, PIL and labels are acceptable from a clinical perspective. The SmPC is consistent with that for the innovator product. The PIL is consistent with the details in the SmPC and in line with the current guidance. The labelling is in line with current guidance.

Clinical Expert Report (Clinical Overview)
The clinical overview has been written by an appropriately qualified physician and is a suitable summary of the clinical aspects of the dossier.

Pharmacovigilance System and Risk Management Plan
The Pharmacovigilance System, as described by the applicant, fulfils the requirements and provides adequate evidence that the applicant has the services of a qualified person responsible for pharmacovigilance and has the necessary means for the notification of any adverse reaction suspected of occurring either in the Community or in a third country.

Suitable justification has been provided for not submitting a risk management plan for this product.

Conclusion
The grant of a Marketing Authorisation is recommended.
IV OVERALL CONCLUSION AND BENEFIT-RISK ASSESSMENT

QUALITY
The important quality characteristics of Ibandronic Acid 6 mg Concentrate for Solution for Infusion are well-defined and controlled. The specifications and batch analytical results indicate consistency from batch to batch. There are no outstanding quality issues that would have a negative impact on the benefit/risk balance.

NON-CLINICAL
No new non-clinical data were submitted and none are required for applications of this type.

EFFICACY
No new clinical data were submitted for this application. No bioequivalence studies were submitted or required for this application.

SAFETY
No new or unexpected safety concerns arose from this application.

PRODUCT LITERATURE
The SmPC, PIL and labelling are satisfactory and consistent with those for the reference product, where appropriate and in line with current guidance.

BENEFIT-RISK ASSESSMENT
The quality of the products is acceptable, and no new non-clinical or clinical safety concerns have been identified. The data supplied support the claim that the applicant’s product and the innovator product are interchangeable. Extensive clinical experience with ibandronic acid is considered to have demonstrated the therapeutic value of the compound. The benefit/risk balance is therefore considered to be positive.
Module 6

STEPS TAKEN AFTER INITIAL PROCEDURE - SUMMARY

<table>
<thead>
<tr>
<th>Date submitted</th>
<th>Application type</th>
<th>Scope</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>